USSF's $15M Lehigh Valley Boost, 100+ Jobs and Cutting-Edge Tech

US Specialty Formulations (USSF), a pharmaceutical services provider for healthcare, diagnostics, and drug developers, is investing $15 million to expand its Lehigh Valley biopharma facility in Allentown. This significant expansion will create over 100 new jobs. The project includes the addition of advanced clean room suites and cutting-edge automated packaging and inspection equipment. By increasing the facility's clean room production capacity by over 2.5 times, USSF will be well-positioned to take on larger projects and support the growth of both new and existing clients once the expansion is completed at the end of 2025.

Clean rooms are crucial for maintaining product quality, safety, and compliance with cGMP standards, providing a sterile environment essential for the production of injectables, such as small molecules, botanicals, and vaccines. Founded in 2013 by Dr. Kyle Flanigan, CEO, and Dr. Garry Morefield, COO, USSF started with their first certified clean room at Ben Franklin Technical Incubator. This expansion marks the third generation of clean rooms for USSF, integrating the core principles of cGMP and quality.

Dr. Flanigan, said “This expansion is a transformative step for USSF. By investing in cutting-edge technology and streamlining our manufacturing processes, we are raising the bar for ourselves and reaffirming our commitment to delivering innovative pharmaceutical solutions that reduce the risk profile of new drug development or contract manufacturing and ultimately improve patient lives. This expansion empowers our dedicated team to serve our partners and clients worldwide more effectively.”

USSF provides a diverse suite of services, from drug research and development to contract manufacturing, private label formulations, and small molecule pharmaceuticals. The company has gained recognition for its groundbreaking work on QYNDR, an innovative oral vaccine platform. Notably, QYNDR became the first self-administered, drinkable vaccine, having successfully completed its Phase I clinical trial in 2023.